Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 4,268 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ADM Clear all

Conditions: Pulse Oximetry
Interventions: Philips MR400 Pro MRI Patient Monitor; Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Louisville, Colorado

Conditions: HIV, Sexually Transmitted Infections
Interventions: Latino STYLE; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 14 Years and older
Enrollment: 542 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Body Image, Self Esteem, Weight Loss, Health Behavior, Health-Related Behavior, Health Knowledge, Attitudes, Practice
Interventions: FASTer Way Intervention, Control Group Intervention; Other
Lead sponsor: Applied Science & Performance Institute; Industry
Eligibility: 30 Years to 55 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Chronic Rhinosinusitis (Diagnosis)
Interventions: Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 1, Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 2; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 90 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Pain Management, Opioid Use, Prostate Cancer
Interventions: Oxycodone, Acetaminophen, Ketamine, Ketorolac; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years to 75 Years · Male only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Arrhythmia
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: PTSD
Interventions: Supported Education, General Peer Support; Other
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Bedford, Massachusetts

Conditions: HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions: Cyclophosphamide, Docetaxel, Doxorubicin, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Trastuzumab; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 3,270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2025
U.S. locations: 1259
States / cities: Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 797 more

Conditions: Breast Cancer
Interventions: paclitaxel, Trastuzumab, Pertuzumab, carboplatin, Breast surgery, AC; Drug · Procedure
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Providence, Rhode Island

Conditions: Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions: L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone, vincristine sulfate, epratuzumab, cytarabine, prednisone, pegaspargase, dexrazoxane hydrochloride, methotrexate, etoposide, cyclophosphamide, leucovorin calcium, filgrastim; Drug · Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: 2 Years to 31 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 42
States / cities: Birmingham, Alabama • Loma Linda, California • Long Beach, California + 36 more

Conditions: Traumatic Brain Injury, Ischemic Stroke, Intracerebral Hemorrhage
Interventions: Decision Aid; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: New Haven, Connecticut • Worcester, Massachusetts

Conditions: Breast Cancer
Interventions: Biopsy, Serum Collection, Urine Collection, Doxorubicin, Cyclophosphamide, Capecitabine, Vinorelbine, Gemcitabine; Procedure · Drug
Lead sponsor: Hoosier Cancer Research Network; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 10
States / cities: Bloomington, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 4 more

Conditions: Sarcoma
Interventions: filgrastim, cisplatin, doxorubicin hydrochloride, ifosfamide, leucovorin calcium, methotrexate, trimetrexate glucuronate, surgical procedure; Biological · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 30 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma
Interventions: DEB-TACE, Sorafenib; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 6
States / cities: Birmingham, Alabama • Los Angeles, California • Louisville, Kentucky + 3 more

Conditions: MDD
Interventions: Problem Solving Therapy, Evolution, Basic health push app; Other · Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Eating Behavior
Interventions: Savor the Flavor; Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 2 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Breast Cancer
Interventions: Doxorubicin, Cyclophosphamide, Paclitaxel, Sorafenib; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 8
States / cities: Jacksonville, Florida • Orlando, Florida • Louisville, Kentucky + 5 more

Conditions: Autism Spectrum Disorder
Interventions: Students with Autism Accessing General Education, Enhanced Services As Usual; Behavioral · Other
Lead sponsor: University of Rochester; Other
Eligibility: Not listed
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Doxorubicin hydrochloride (liposomal); Drug
Lead sponsor: Sequus Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Disabled Persons
Interventions: Our Peers - Empowerment and Navigational Support - Community Living (OP-ENS - CL); Behavioral
Lead sponsor: Susan Magasi; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: Medigus Ultrasonic Surgical Endostapler (MUSE) Procedure; Device
Lead sponsor: Medigus Ltd; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 11
States / cities: Orange, California • San Diego, California • Gainesville, Florida + 8 more

Conditions: Leukemia
Interventions: cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, imatinib mesylate, methotrexate, methylprednisolone, pegaspargase, vincristine sulfate; Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Glioblastoma
Interventions: MRI-guided Laser Heat Ablation (MLA), Doxorubicin, Blood draw - dendritic cells, Dynamic Susceptibility Contrast Magnetic Resonance Imaging; Device · Drug · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Atherosclerosis, Coronary
Interventions: CCTA; Diagnostic Test
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Buffalo, New York

Search by objective public record fields.

NEXT GEN - PHILIPS OPTIMUS

Randomized Control Trial of Family-Based HIV Prevention for Latinos

The Effectiveness on an Application-Based Lifestyle Change Program on Health in Women

Functional Endoscopic Sinus Surgery Study

Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy

The Effect of General Anesthesia on the Risk for Arrhythmia

Supported Education Pilot

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

Shared Decision Making to Improve Goals-of-Care Decisions for Families of Severe Acute Brain Injury Patients

A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer

Combination Chemotherapy and Surgery in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma

Can Mental Health Apps Work in the Real World? A Feasibility Pilot Study.

Evaluating a Mindful Eating Curriculum, "Savor the Flavor"

Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer

Development and Pilot Testing of the Students With Autism Accessing General Education (SAAGE) Model

Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.

Our Peers - Empowerment and Navigational Support - Community Living (OP-ENS-CL): A Peer Navigator Intervention for Adults With Acquired Physical Disabilities

Medigus Ultrasonic Surgical Endostapler (MUSE) Registry

Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme

Validation of a Computed Tomography (CT) Based Fractional Flow Reserve (FFR) Software Using the 320 Detector Aquilion ONE CT Scanner.